PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)

被引：3
|
作者：
Alsina, M.
Lonial, S.
Weber, D. M.
Coutre, S. E.
Kang, B. P.
Glynos, T.
Warsi, G.
Snodgrass, S. M.
Richardson, P. G.
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS308
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2)
    Alsina, Melissa
    Richardson, Paul Gerard Guy
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Gasparetto, Cristina
    Mukhopadhyay, Sutapa
    Ondovik, Michael S.
    Khan, Mahmudul H.
    Paley, Carole S.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Spencer, A.
    Taylor, K.
    Lonial, S.
    De la Rubia, J.
    Facon, T.
    Bengoudifa, R.
    Klebsattel, M.
    Hazell, K.
    Bourquelot, P.
    Rossi, J. F.
    Harousseau, J. L.
    Jagannath, S.
    Wolf, J.
    San Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 158 - 158
  • [3] PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Alsina, M.
    Weber, D.
    Coutre, S.
    Lonial, S.
    Gasparetto, C.
    Warsi, G.
    Ondovik, M.
    Mukhopadhyay, S.
    Paley, C.
    Schlossman, R.
    HAEMATOLOGICA, 2012, 97 : 338 - 338
  • [4] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Jakubowiak, Andrzej J.
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, Claire
    Lynch, Mark John
    Bleickardt, Eric W.
    Jou, Ying-Ming
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Sezer, O.
    Siegel, D.
    Guenther, A.
    Blade, J.
    Prosser, I.
    Hazell, K.
    Bengoudifa, R.
    Klebsattel, M.
    Bourquelot, P.
    Cavo, M.
    Goebeler, M.
    Niederweiser, D.
    Milder, M.
    Boccadoro, M.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155
  • [7] Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM)
    Mateos, M.
    Spencer, A.
    Taylor, K.
    Lonial, S.
    De La Rubia, J.
    Facon, T.
    Bengoudifa, B.
    Hazell, K.
    Bourquelot, P. M.
    San-Miguel, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Harrison, Beverly
    Lau, Kenneth
    Hilder, Brandi
    Ptaszynski, Ann
    Rush, Selena A.
    Kaufman, Jonathan L.
    Burt, Steven Michael
    BLOOD, 2013, 122 (21)
  • [9] PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
    Richardson, Paul G.
    Schlossman, Robert L.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Gasparetto, Cristina
    Mukhopadhyay, Sutapa
    Ondovik, Michael S.
    Khan, Mahmudul
    Paley, Carole S.
    Lonial, Sagar
    BLOOD, 2013, 122 (14) : 2331 - 2337
  • [10] Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
    San-Miguel, J. F.
    Sezer, O.
    Siegel, D. S.
    Guenther, A.
    Blade, J.
    Prosser, I. W.
    Bengoudifa, B.
    Klebsattel, M.
    Bourquelot, P. M.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345